Kadmon, Jinghua collaborate in China

Monday, November 23, 2015

Kadmon has announced a new collaboration and license agreement with China’s Jinghua Pharmaceutical to discover, develop and commercialize Kadmon’s fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China. Kadmon also has licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market.

[Read More]

EffRx Pharmaceuticals, Kadmon form global collaboration

Wednesday, March 19, 2014

EffRx Pharmaceuticals, a provider of innovative drug delivery technologies that improve efficacy and tolerability of existing compounds, has established a worldwide collaboration with Kadmon, a global biopharmaceutical company, under which EffRx will generate effervescent formulations of products to be developed by Kadmon in both adult and pediatric orphan indications. Financial terms were not disclosed.

[Read More]